D. Boral Capital Reaffirms Buy Rating for FibroBiologics (NASDAQ:FBLG)

D. Boral Capital reaffirmed their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a research note released on Thursday morning,Benzinga reports. D. Boral Capital currently has a $16.00 target price on the stock.

Other equities research analysts have also issued reports about the company. Rodman & Renshaw started coverage on FibroBiologics in a research report on Thursday, December 12th. They issued a “buy” rating and a $12.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of FibroBiologics in a report on Thursday, February 13th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $13.00.

FibroBiologics Stock Up 4.4 %

Shares of NASDAQ FBLG opened at $1.19 on Thursday. The company has a 50-day moving average of $1.74 and a 200 day moving average of $2.28. FibroBiologics has a 12-month low of $0.98 and a 12-month high of $14.70.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in shares of FibroBiologics by 90.0% in the 3rd quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock valued at $1,854,000 after purchasing an additional 284,047 shares during the last quarter. Barclays PLC lifted its position in FibroBiologics by 363.2% in the third quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after buying an additional 31,331 shares during the last quarter. Jane Street Group LLC acquired a new position in FibroBiologics in the third quarter valued at about $37,000. State Street Corp boosted its stake in FibroBiologics by 26.5% during the third quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after buying an additional 99,789 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of FibroBiologics during the third quarter valued at about $32,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.